An open-label study is a clinical trial without blinding of the treatment allocation: Participants, the study team and usually also the sponsor know which intervention is being administered. The open design can be scientifically and ethically appropriate, but increases the risk of bias through expectations, behavior and assessment. Its justification as well as measures to limit bias belong in the study protocol and statistical planning.<\/p>\n
An open study is considered when a credible blinding is not practical or would cause disproportionate burdens. Examples are interventions with clearly distinguishable routes of administration, surgical procedures, medical devices with recognizable application or dose adjustments that require knowledge of the treatment. Early clinical trials focusing on safety, tolerability or pharmacokinetic data can also be designed open-label.<\/p>\n
An open-label extension often follows a blinded core study. It can enable further treatment and the collection of long-term data after the controlled comparison phase has been completed. However, the open follow-up phase does not retroactively replace the controlled efficacy comparison. Its objectives, inclusion rules, endpoints and the interpretation of the data must be defined independently and in advance.<\/p>\n
If the treatment is known, participants’ expectations can influence adherence and reported symptoms. Investigators may unconsciously act differently during examination, documentation or decision on concomitant measures. Subjective endpoints such as pain, quality of life or global clinical assessments are particularly susceptible. Dropouts, additional contacts and the reporting of adverse events can also be influenced differently between treatments.<\/p>\n
The open design therefore requires a risk-adequate combination of protective measures. Objective or centrally collected endpoints, standardized examination procedures, pre-defined decision criteria and an independent, blinded endpoint assessment are possible. Data management must support completeness and timely plausibility checks. ICH E8(R1) requires quality planning that considers factors that are essential for the reliability of the study results; in open-label studies, the systematic limitation of avoidable bias is such a factor.<\/p>\n
The measures must match the specific source of error. Central image reading, for example, can reduce observation bias in imaging endpoints, while it does not completely eliminate expectations in self-reported symptoms. Transparent documentation of deviations, missing data and therapy changes facilitates the subsequent evaluation of robustness.<\/p>\n
Open label means that the treatment allocation is not concealed. Blinding, on the other hand, is a procedure that deliberately prevents knowledge of the allocation among certain stakeholders in order to reduce bias. Implementation can occur, for example, via identical comparator treatments, separated roles or controlled randomization processes. Which persons must remain blinded depends on the risks of the design and the respective tasks.<\/p>\n
A double-blind study is a form of blinding in which typically both participants and the directly treating or evaluating persons do not know the allocation. A single-blind study shields only one of these groups. Open-label study, blinding and double-blind remain separate glossary terms: An open design is not an incomplete double-blind study, but a deliberate design decision, the effects of which must be managed transparently.<\/p>\n
The decision for an open design influences the choice of endpoints, the training of the study centers, data collection and the interpretation of the results. According to ICH E6(R3), clinical trials must be planned scientifically sound and conducted in such a way that participant protection and reliable results are ensured. In an open-label study, protocol, monitoring plan and analysis plan must therefore particularly clearly describe where knowledge of the treatment can influence decisions or data and how this risk is controlled.<\/p>\n
Full-service CROs such as Mediconomics support the design justification, the development of bias minimization measures, the preparation of the protocol and statistical analysis plan as well as data management and central monitoring. This includes the specification of standardized endpoint collections, the organization of an optionally blinded endpoint assessment, the training of study centers and the comprehensible presentation of the open design limitations for the clinical study report.<\/p>\n
Are results from open-label studies fundamentally of less value?<\/strong><\/p>\n No. Their informative value depends on the research question, the endpoints, the comparison and the planned protective measures. For subjective endpoints, the risk of bias is usually higher; an open design must then be particularly convincingly justified and safeguarded.<\/p>\n Can an open-label study be randomized?<\/strong><\/p>\n Yes. Randomization determines the allocation to treatments or sequences. Open label, on the other hand, describes whether this allocation is concealed. A randomized study can therefore be conducted open-label.<\/p>\n What is the purpose of an open-label extension?<\/strong><\/p>\n It frequently enables the further observation of safety, tolerability or treatment under open conditions following a controlled phase. Statements on the comparative proof of efficacy must thereby consider the lack of blinding and the previous treatment history.<\/p>\n An open-label study is a clinical trial without blinding of the treatment allocation: Participants, the study team and usually also the sponsor know which intervention is being administered. The open design can be scientifically and ethically appropriate, but increases the risk of bias through expectations, behavior and assessment. Its justification as well as measures to […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6793","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":1,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6793\/revisions"}],"predecessor-version":[{"id":7417,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6793\/revisions\/7417"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6793"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory references<\/h2>\n
\n